Ranolazine improves endothelial function in patients with stable coronary artery disease

Coronary Artery Disease

Volumn 20, Issue 5, 2009, Pages 343-347

  Deshmukh, Smriti H ^b   Patel, Snehal R ^b   Pinassi, Elsa ^b   Mindrescu, Catalin ^b   Hermance, Eileen V ^b   Infantino, Michael N ^b   Coppola, John T ^b   Staniloae, Cezar S ^a  

^a ST VINCENT S HOSPITAL MANHATTAN   (United States)

^b NONE

Author keywords

Coronary artery disease; Endothelial function; Peripheral artery tonometry; Ranolazine

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N(G),N(G) DIMETHYLARGININE; NITRATE; PLACEBO; RANOLAZINE;

ABNORMAL LABORATORY RESULT; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART RATE; HUMAN; INFLAMMATION; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYNCOPE; TONOMETRY; TREATMENT DURATION; TREATMENT OUTCOME;

ACETANILIDES; AGED; ARGININE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPEREMIA; INFLAMMATION MEDIATORS; MALE; MANOMETRY; MIDDLE AGED; PIPERAZINES; TIME FACTORS; TREATMENT OUTCOME; VASODILATION;

EID: 68049137918     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32832a198b     Document Type: Article

References (27)

1. Chaitman B, Pepine C, Parker J, Skopal J, Chumakova G, Kuch J, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004; 291:309-316. (Pubitemid 38101603)
2. Chaitman B, Skettino S, Parker J, Hanley P, Meluzin J, Kuch J, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J AmColl Cardiol 2004; 43:1375-1382. (Pubitemid 38496341)
3. Antzelevitch C, Belardinelli L, Zygmunt A, Burashnikov A, Di Diego JM, Fish JM, et al. Electrophysiological effects of ranolzaine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110:904-910. (Pubitemid 39136212)
4. Belardinelli L, Antzelevitch C, Fraser H. Inhibition of late (sustained/ persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J 2004; 6:13-17.
5. Sabbah H, Chandler M, Mishima T, Suzuki G, Chaudhry P, Nass O, et al. Ranolazine, a partially fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 2002; 8:416-422. (Pubitemid 36055744)
6. Chandler M, Stanley W, Morita H, Suzuki G, Roth BA, Blackburn B, et al. Short-term treatment with ranolazine improves mechanical efficacy in dogs with chronic heart failure. Circ Res 2002; 91:278-280. (Pubitemid 34976992)
7. Gralinski M, Black S, Kilgore K, Chou AY, McCormack JG, Lucchesi BR. Cardioprotective effects of ranolazine in the isolated perfused rabbit heart. Cardiovasc Res 1994; 28:1231-1237. (Pubitemid 24264731)
8. Ludmer P, Selwyn A, Shook T. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315:1046-1051. (Pubitemid 17170620)
9. Schachinger V, Britten M, Zeiher A. Prognostic impact on coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101:1899-1906. (Pubitemid 30225269)
10. Al Suwaidi J, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101:948-954. (Pubitemid 30131694)
11. Bonetti PO, Barsness GW, Keelan PC, Schnell TI, Pumper GM, Kuvin JT, et al. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol 2003; 41:1761-1768. (Pubitemid 36584250)
12. Kuvin J, Patel A, Sliney K, Pandian NG, Sheffy J, Schnall RP, et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J 2003; 146:168-174. (Pubitemid 36851317)
13. Nohria A, Gerhard-Herman M, Creager M, Hurley S, Mitra D, Ganz P. Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J Appl Physiol 2006; 101:545-548. (Pubitemid 44162364)
14. Belardinelli L, Shryock J, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006; 92:6-14. (Pubitemid 43974036)
15. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L; ERICA Investigators. Anti-anginal efficacy of ranolazine when added to maximal therapy with conventional therpay: the efiicacy of ranolazine in chronic angina trial. Circulation 2005; 48:566-575.
16. Walsh KB, Wolf MB, Fan J. Voltage-gated sodium channels in cardiac microvascular endothelial cells. Am J Physiol 1998; 274:H506-H512. (Pubitemid 128655879)
17. Traub O, Ishida T, Ishida M, Tupper JC, Berk BC. Shear stress-mediated extracellular signal-regulated kinase activation is regulated by sodium in endothelial cells. Potential role for a voltage-dependent sodium channel. J Biol Chem 1999; 274:20144-20150. (Pubitemid 129519482)
18. Boger R. The emerging role ADMA as a novel cardiovascular risk factor. Cardiovasc Res 2003; 59:824-833.
19. Cooke J. Asymmetrical dimethylarginine: the Uber marker? Circulation 2004; 109:1813-1818.
20. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004; 24:1023-1030. (Pubitemid 38737826)
21. Rathel T, Leikert J, Vollmar A, Dirsch V. Application of 4,5-diaminofluorescein to reliably measure nitric oxide released from endothelial cells in vitro. Biol Proced Online 2003; 5:136-142. (Pubitemid 38097508)
22. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S, et al. Asymmetric dimethlyarginine produces vascular lesions in endothelial nitric oxide synthasedeficient mice. Arterioscl Thromb Vasc Biol 2004; 24:1682-1688.
23. Jain M, Ridker P. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nature reviews. Drug Discov 2005; 4: 977-987.
24. John S, Schneider MP, Delles C, Jacobi J, Schmieder RE. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005; 149:e473. (Pubitemid 40585410)
25. Dhalla A, Liu D, Santikul M, Belardinelli L. Ranolazine increases glucose stimulated insulin secretion in rats. J Am Coll Cardiol 2008; 51 (Suppl A):A321.
26. Kuvin JT, Mammen A, Mooney P, Alsheikh-Ali AA, Karas RH. Assessment peripheral vascular endothelial function in the ambulatory setting. Vasc Med 2007; 12:13-16. (Pubitemid 46578783)
27. Bonetti P, Pumper G, Higano S, Holmes D, Kuvin J, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004; 44:2137-2141. (Pubitemid 39576032)